Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky [Yahoo! Finance]
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates